cervarix suspension for injection
glaxosmithkline biologicals s.a. - human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - suspension for injection - 20mcg/dose+ 20mcg/dose
priorix powder lyophilized and solvent for solution for injection
glaxosmithkline biologicals s.a. - live attenuated measles virus(schwarz strain), live attenuated mumps virus(rit 4385 strain), live attenuated rubella virus(wistar ra 27/3 strain) - powder lyophilized and solvent for solution for injection - not less than 103.0ccid50/dose+ not less than 103.7ccid50/dose+ not less than 103.0ccid50/dose
priorix powder lyophilized and solvent for solution for injection
glaxosmithkline biologicals s.a. - live attenuated measles virus(schwarz strain), live attenuated mumps virus(rit 4385 strain), live attenuated rubella virus(wistar ra 27/3 strain) - powder lyophilized and solvent for solution for injection - not less than 103.0ccid50/dose+ not less than 103.7ccid50/dose+ not less than 103.0ccid50/dose
infanrix hexa powder and suspension for suspension for injection
glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose+ 10mcg/dose+ 40d-antigen unit/dose+ 8d-antig
sevenfact- coagulation factor viia recombinant human kit
laboratoire français du fractionnement et des biotechnologies société anonyme (lfb s.a.) - coagulation factor viia recombinant human (unii: ac71r787ov) (coagulation factor viia recombinant human - unii:ac71r787ov) - sevenfact [coagulation factor viia (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia a or b with inhibitors. limitation of use: sevenfact is not indicated for the treatment of patients with congenital factor vii deficiency. sevenfact is contraindicated in - known allergy to rabbits or rabbit proteins. exposure to sevenfact in these patients can result in severe hypersensitivity reaction. - patients with severe hypersensitivity reaction to sevenfact or any of its components. exposure to sevenfact in these patients can result in severe hypersensitivity reaction. risk summary there are no adequate and well-controlled studies using sevenfact in pregnant women to determine whether there is a drug-associated risk. animal studies evaluating the embryo-fetal teratogenic potential of sevenfact have not been conducted. it is unknown whether sevenfact can cause fetal harm when administered to a pregnant
clopidogrel-asteria tablets film-coated
one pharma industrial pharmaceutical company societe anonyme - clopidogrel (clopidogrel bisulfate) - tablets film-coated - 75mg
clopidogrel-asteria tablets film-coated
one pharma industrial pharmaceutical company societe anonyme - clopidogrel (clopidogrel bisulfate) - tablets film-coated - 75mg
panadol duo 500 mg/200 mg film-coated tablets
haleon hellas single member societe anonyme, under the distinctive title of haleon hellas, 274, kifissias ave, 15232 chalandri, athens, greece - film-coated tablet - paracetamol 500 mg ibuprofen 200 mg - antiinflammatory and antirheumatic products
mg-2000 - nettoyant desinfectant liquide
societe multhi inc. - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - liquid - .8%; .8% - benzalkonium chloride .8%; alkyl dimethyl ethylbenzyl ammonium chloride .8% - disinfectants (for agents used on object)
pectolyn sirop syrup
societe morex enrg - cocillana; myroxylon balsamum - syrup - 30mg; 0.675ml - cocillana 30mg; myroxylon balsamum 0.675ml - herbs and natural products